Switching between P2Y12 antagonists - From bench to bedside.
作者： Marek Postuła , Aleksandra Gasecka , Michał Konwerski , Justyna Pordzik , Aleksandra Soplińska
DOI: 10.1016/J.VPH.2019.01.003
关键词:
摘要: Platelet P2Y12 receptors play a key role in platelet activation and thrombus formation. Accordingly, receptor antagonists are the cornerstone of secondary prevention atherothrombotic events patients undergoing percutaneous coronary intervention (PCI). The availability different oral (clopidogrel, prasugrel, ticagrelor) along with introduction first intravenous antagonist cangrelor offer an opportunity to individualize antiplatelet therapy according changing clinical setting. recent International Expert Consensus provided recommendations on switching between antagonists. While consensus greatly helps guide antagonists, number controversial scenarios remain where evidence regarding optimal switch strategy is scarce. In such scenarios, understanding (i) pharmacological properties (ii) from pharmacodynamics studies, trials registries, (iii) factors affecting efficacy safety all summarized below, crucial choose strategy.
narcis.nl参考文章(67)
Isabell Bernlochner, Dirk Sibbing, Thienopyridines and Other ADP-Receptor Antagonists Antiplatelet Agents. pp. 165- 198 ,(2012) , 10.1007/978-3-642-29423-5_7
Dominick J. Angiolillo, Nicholas Curzen, Paul Gurbel, Paul Vaitkus, Fred Lipkin, Wei Li, Joseph A. Jakubowski, Marjorie Zettler, Mark B. Effron, Dietmar Trenk, Pharmacodynamic Evaluation of Switching From Ticagrelor to Prasugrel in Patients With Stable Coronary Artery Disease Journal of the American College of Cardiology. ,vol. 63, pp. 1500- 1509 ,(2014) , 10.1016/J.JACC.2013.11.032
Renli Teng, Ticagrelor: Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Profile: An Update Clinical Pharmacokinetics. ,vol. 54, pp. 1125- 1138 ,(2015) , 10.1007/S40262-015-0290-2
Fabiana Rollini, Francesco Franchi, Dominick J. Angiolillo, Switching P2Y12-receptor inhibitors in patients with coronary artery disease Nature Reviews Cardiology. ,vol. 13, pp. 11- 27 ,(2016) , 10.1038/NRCARDIO.2015.113
T. GEISLER, D. GRAß, B. BIGALKE, K. STELLOS, T. DROSCH, K. DIETZ, C. HERDEG, M. GAWAZ, The Residual Platelet Aggregation after Deployment of Intracoronary Stent (PREDICT) score. Journal of Thrombosis and Haemostasis. ,vol. 6, pp. 54- 61 ,(2007) , 10.1111/J.1538-7836.2007.02812.X
Terry K. W. Ma, Yat-Yin Lam, Victoria P. Tan, Bryan P. Yan, Variability in response to clopidogrel: how important are pharmacogenetics and drug interactions? British Journal of Clinical Pharmacology. ,vol. 72, pp. 697- 706 ,(2011) , 10.1111/J.1365-2125.2011.03949.X
P Savi, JM Pereillo, MF Uzabiaga, J Combalbert, C Picard, JP Maffrand, M Pascal, JM Herbert, None, Identification and biological activity of the active metabolite of clopidogrel. Thrombosis and Haemostasis. ,vol. 84, pp. 891- 896 ,(2000) , 10.1055/S-0037-1614133
N. L. DOVLATOVA, J. A. JAKUBOWSKI, A. SUGIDACHI, S. HEPTINSTALL, The reversible P2Y antagonist cangrelor influences the ability of the active metabolites of clopidogrel and prasugrel to produce irreversible inhibition of platelet function. Journal of Thrombosis and Haemostasis. ,vol. 6, pp. 1153- 1159 ,(2008) , 10.1111/J.1538-7836.2008.03020.X
Marta Karaźniewicz-Łada, Dorota Danielak, Paweł Burchardt, Łukasz Kruszyna, Anna Komosa, Maciej Lesiak, Franciszek Główka, Clinical pharmacokinetics of clopidogrel and its metabolites in patients with cardiovascular diseases. Clinical Pharmacokinectics. ,vol. 53, pp. 155- 164 ,(2014) , 10.1007/S40262-013-0105-2
Steven R. Steinhubl, Jennifer J. Oh, Julie H. Oestreich, Suellen Ferraris, Richard Charnigo, Wendell S. Akers, Transitioning patients from cangrelor to clopidogrel: Pharmacodynamic evidence of a competitive effect Thrombosis Research. ,vol. 121, pp. 527- 534 ,(2008) , 10.1016/J.THROMRES.2007.05.020